Lance brings over 20 years industry experience and over the past ten years has focused his work in business development at large pharmaceutical companies and small biotechs.  At KSQ he’s led three major transactions with Ono, Takeda and Roche resulting in significant runway extension and partners poised to leverage KSQ discoveries.  Before joining KSQ, Lance was the Head of BD at Xilio Therapeutics where he focused on early-stage collaborations with pharma resulting in a deal with Merck. Previously, he was Head of the Roche Boston Innovation Hub, focused on early-stage therapeutics as well as accessing innovative research and technologies through collaboration, licensing, or M&A in the academic, pharma, and biotech community. Before Roche he held many roles of increasing responsibility at Novartis Institutes for BioMedical Research (NIBR) including translational research, alliance management and BD.  Lance has worked on deals totaling more than 5 billion dollars from discovery collaborations to Phase I programs.  Lance holds a Master’s in biology from Harvard University Extension School and a Bachelor of Science in Biology from University of Michigan.